Selective, brain penetrant GABAB receptor antagonist (IC50 = 34 μM as measured in rat cortical membranes). Has higher affinity for postsynaptic versus presynaptic receptors.
Sold with the permission of Novartis Pharma AG
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 225.22. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.44 mL||22.2 mL||44.4 mL|
|5 mM||0.89 mL||4.44 mL||8.88 mL|
|10 mM||0.44 mL||2.22 mL||4.44 mL|
|50 mM||0.09 mL||0.44 mL||0.89 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Hao et al (1994) Intrathecal γ-aminobutyric acidB (GABAB) receptor antagonist CGP 35348 induces hypersensitisation to mechanical stimuli in the rat. Neurosci.Lett. 182 299 PMID: 7715832
Olpe et al (1990) CGP 35348: a centrally active blocker of GABAB receptors. Eur.J.Pharmacol. 187 27 PMID: 2176979
Staubli et al (1999) GABAB receptor antagonism: facilitatory effects on memory parallel those on LTP induced by TBS but not HFS. J.Neurosci. 19 4609 PMID: 10341258
Sutor and Luhmann (1998) Involvement of GABAB receptors in convulsant-induced epileptiform activity in rat neocortex in vitro. Eur.J.Neurosci. 10 3417 PMID: 9824455
If you know of a relevant reference for CGP 35348, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Brain penetrant selective GABAB antagonists Receptors CGP35348 GABAB Receptors
7 Citations for CGP 35348
Citations are publications that use Tocris products. Selected citations for CGP 35348 include:
Huang et al (2015) The in vitro generation of lung and airway progenitor cells from human pluripotent stem cells. Br J Pharmacol 10 413 PMID: 25654758
Xia et al (2014) Regulation of action potential waveforms by axonal GABAA receptors in cortical pyramidal neurons. PLoS One 9 e100968 PMID: 24971996
Aubdool et al (2014) TRPA1 is essential for the vascular response to environmental cold exposure. Neuron 5 5732 PMID: 25501034
Gantz et al (2013) Spontaneous inhibitory synaptic currents mediated by a G protein-coupled receptor. Cell Metab 78 807 PMID: 23764286
Gantz et al (2011) Loss of Mecp2 in substantia nigra dopamine neurons compromises the nigrostriatal pathway. J Neurosci 31 12629 PMID: 21880923
Milenković et al (2007) Development of chloride-mediated inhibition in neurons of the anteroventral cochlear nucleus of gerbil (Meriones unguiculatus). J Neurophysiol 98 1634 PMID: 17596413
Wood et al (2000) The human GABA(B1b) and GABA(B2) heterodimeric recombinant receptor shows low sensitivity to phaclofen and saclofen. Nat Commun 131 1050 PMID: 11082110
Do you know of a great paper that uses CGP 35348 from Tocris? If so please let us know.
Literature in this Area
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.